Back to results
US 2025/0375440 A1Published application
Composition and method of treating cancer associated with egfr mutation
AssigneeBeyondSpring Pharmaceuticals, Inc.
InventorsLan HUANG, George Kenneth LLOYD
Life of this patent
Estimating the term…
Abstract
Disclosed herein are plinabulin and its use for treating a cancer or tumor characterized by expression of a mutant form of an epidermal growth factor receptor (EGFR) protein, comprising administering plinabulin to a subject in need thereof.
Claims20
1-22. (canceled)
A method of therapeutically treating a cancer, consisting of:
- administering an effective amount of plinabulin, or a pharmaceutically acceptable salt thereof, to a human subject in need thereof, wherein the effective amount of plinabulin, or the pharmaceutically acceptable salt thereof, is from about 20 mg/m2 to about 30 mg/m2 of body surface area, and
- administering an effective amount of osimertinib, or a pharmaceutically acceptable salt thereof, to the human subject, wherein the effective amount of osimertinib, or the pharmaceutically acceptable salt thereof, is from about 60 mg to about 100 mg per day, wherein the cancer is characterized by expression of a mutant form of an epidermal growth factor receptor (EGFR) protein, and
- wherein the cancer is lung cancer.
A method of inhibiting progression of a cancer, consisting of:
- administering an effective amount of plinabulin, or a pharmaceutically acceptable salt thereof, to a human subject in need thereof, wherein the effective amount of plinabulin, or the pharmaceutically acceptable salt thereof, is from about 20 mg/m2 to about 30 mg/m2 of body surface area, and
- administering an effective amount of osimertinib, or a pharmaceutically acceptable salt thereof, to the human subject, wherein the effective amount of osimertinib, or the pharmaceutically acceptable salt thereof, is from about 60 mg to about 100 mg per day, wherein the cancer is characterized by expression of a mutant form of an EGFR protein, and
- wherein the cancer is lung cancer.
A method of therapeutically treating a cancer, consisting of:
- co-administering plinabulin, or a pharmaceutically acceptable salt thereof, and osimertinib, or a pharmaceutically acceptable salt thereof, to a human subject in need thereof,
- wherein the effective amount of plinabulin, or the pharmaceutically acceptable salt thereof, is from about 20 mg/m2 to about 30 mg/m2 of body surface area,
- wherein the effective amount of osimertinib, or the pharmaceutically acceptable salt thereof, is from about 60 mg to about 100 mg per day,
- wherein the cancer is characterized by expression of a mutant form of an epidermal growth factor receptor (EGFR) protein, and
- wherein the cancer is lung cancer.
2 more elements
Dependencies are inferred from the claim text.